COPENHAGEN, Denmark, Jan. 7, 2025 /PRNewswire/ -- Vesper Bio ApS ('Vesper' or 'the Company'), a clinical stage biotech and world leader in sortilin receptor biology, today announces the initiation of ...
Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results